阿仑膦酸钠联合阿托伐他汀治疗糖尿病性骨质疏松临床研究

Clinical Study on Alendronate Sodium Combined with Atorvastatin in Treatment of Patients with Diabetic Osteoporosis

目的观察阿仑膦酸钠联合阿托伐他汀治疗糖尿病性骨质疏松症的临床效果。方法选择2017年6—9月收治的2型糖尿病性骨质疏松症120例。按治疗方法分为研究组70例和对照组50例。2组均给予基础治疗,对照组给予阿仑膦酸钠治疗,研究组在对照组基础上给予阿托伐他汀治疗。观察2组疼痛数字评分(NRS)、临床疗效、骨密度及药物不良反应发生情况。结果研究组总有效率高于对照组(P <0. 05)。研究组治疗后NRS评分、骨密度均高于对照组(P <0. 05)。2组不良反应发生率比较差异无统计学意义(P> 0. 05)。结论阿仑膦酸钠联合阿托伐他汀治疗糖尿病性骨质疏松可缓解临床症状,提高骨密度,且较安全。

Objective To observe clinical effect of Alendronate Sodium combined with Atorvastatin in treatment of patients with diabetic osteoporosis. Methods A total of 120 patients with type 2 diabetic osteoporosis admitted from June to September 2017 were divided into study group （n = 70） and control group （n = 50） according to therapeutic methods. All patients received basic treatment, and then control group was treated with Alendronate Sodium, while study group was added with Atorvastatin on the basis of treatment for control group. Numerical rating scale （NRS） score, curative effect, bone density and incidence rate of adverse drug reactions were observed in two groups. Results The total ef- fective rate in study group was significantly higher than that in control group （P 〈0.05）. After treatment, values of NRS score and bone density in study group were significantly higher than those in control group （P 〈 0.05）. There was no significant difference in incidence rate of adverse reactions between two groups （P 〉 0.05）. Conclusion Alendronate Sodium combined with Atorvastatin in treatment of patients with diabetic osteoporosis may relieve clinical symptonls and increase bone density with safety.